These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 16979777)

  • 1. Neutralizing antibodies to interferon alpha in a chronic hepatitis C patient non-responder to pegylated interferon.
    Santantonio T; Milella M; Antonelli G; Scagnolari C
    J Hepatol; 2006 Nov; 45(5):759-61. PubMed ID: 16979777
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C.
    van der Eijk AA; Vrolijk JM; Haagmans BL
    N Engl J Med; 2006 Mar; 354(12):1323-4. PubMed ID: 16554542
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevalence and therapeutic significance of anti-interferon antibodies in hepatitis C virus/HIV-co-infected patients.
    Ramos B; Sheldon J; Ruiz-Sancho A; Toro C; Ríos P; Soriano V
    AIDS; 2007 Mar; 21(5):652-3. PubMed ID: 17314531
    [No Abstract]   [Full Text] [Related]  

  • 4. Sustained remission of chronic hepatitis C after a change to human leukocyte interferon-alpha in a difficult-to-treat patient with breakthrough phenomenon associated with antibodies against recombinant interferon-alpha.
    Berg T; Hopf U; Schuff-Werner P
    Am J Gastroenterol; 2001 Feb; 96(2):612-4. PubMed ID: 11232730
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pegylated interferons: pharmacological basis].
    Macquin-Mavier I; Hezode C; Dhumeaux D
    Gastroenterol Clin Biol; 2002; 26(8-9):742-7. PubMed ID: 12434079
    [No Abstract]   [Full Text] [Related]  

  • 6. Peginterferon and ribavirin for hepatitis C.
    Evoli A; Servidei S
    N Engl J Med; 2007 Mar; 356(12):1269-70; author reply 1271. PubMed ID: 17380575
    [No Abstract]   [Full Text] [Related]  

  • 7. Intrahepatic interferon-stimulated gene responses: can they predict treatment responses in chronic hepatitis C infection?
    Shackel NA; McCaughan GW
    Hepatology; 2007 Nov; 46(5):1326-8. PubMed ID: 17969041
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapy-induced antibodies against the antiviral and antiproliferative effects of interferons in patients with chronic hepatitis C virus infection.
    Bálint E; Bakay M; Onody K; Farkas F; Horváth G; Tolvaj G; Dávid K; Horányi M; Béládi I
    Acta Microbiol Immunol Hung; 2004; 51(3):359-69. PubMed ID: 15571075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peginterferon and ribavirin for chronic hepatitis C.
    Hoofnagle JH; Seeff LB
    N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366
    [No Abstract]   [Full Text] [Related]  

  • 10. Effectiveness of pegylated interferon/ribavirin combination in 'real world' patients with chronic hepatitis C virus infection.
    Borroni G; Andreoletti M; Casiraghi MA; Ceriani R; Guerzoni P; Omazzi B; Terreni N; Salerno F
    Aliment Pharmacol Ther; 2008 May; 27(9):790-7. PubMed ID: 18298638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated interferon vs standard interferon for chronic hepatitis C.
    Menkes DL
    JAMA; 2005 Mar; 293(11):1323; author reply 1323-4. PubMed ID: 15769962
    [No Abstract]   [Full Text] [Related]  

  • 12. A prospective study of change in visual function in patients treated with pegylated interferon alpha for hepatitis C in the UK.
    Malik NN; Sheth HG; Ackerman N; Davies N; Mitchell SM
    Br J Ophthalmol; 2008 Feb; 92(2):256-8. PubMed ID: 17962387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombotic thrombocytopenic purpura with fatal outcome in a patient with chronic hepatitis C treated with pegylated interferon-a/2b.
    Deutsch M; Manesis EK; Hadziyannis E; Vassilopoulos D; Archimandritis AJ
    Scand J Gastroenterol; 2007 Mar; 42(3):408-9. PubMed ID: 17354123
    [No Abstract]   [Full Text] [Related]  

  • 14. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).
    Reddy KR
    Semin Liver Dis; 2004; 24 Suppl 2():33-8. PubMed ID: 15346244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory activities of IFN-gamma1b in combination with type I IFN: implications for the use of IFN-gamma1b in the treatment of chronic HCV infections.
    Wang T; Blatt LM; Seiwert SD
    J Interferon Cytokine Res; 2006 Jul; 26(7):473-83. PubMed ID: 16800786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term suppressive therapy with pegylated interferon for chronic hepatitis C associated membranoproliferative glomerulonephritis.
    Cua IH; Kwan V; Henriquez M; Kench J; George J
    Gut; 2006 Oct; 55(10):1521-2. PubMed ID: 16966706
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pegylated interferon: new progress in treatment for chronic hepatitis C].
    Boyer N; Marcellin P
    Gastroenterol Clin Biol; 2000; 24(8-9):767-9. PubMed ID: 11011255
    [No Abstract]   [Full Text] [Related]  

  • 18. Adverse response to pegylated interferon therapy in two patients with chronic hepatitis C.
    Thomas WL; Ramos F; Hospenthal DR
    Hawaii Med J; 2003 Aug; 62(8):163-4. PubMed ID: 14533347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chronic hepatitis C. Better treatment outcome with pegylated interferon].
    MMW Fortschr Med; 2001 Mar; 143(13):51. PubMed ID: 11332022
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN.
    Milella M; Antonelli G; Santantonio T; Giannelli G; Currenti M; Monno L; Turriziani O; Pastore G; Dianzani F
    Hepatogastroenterology; 1995 Jul; 42(3):201-4. PubMed ID: 7590565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.